- Sepracor has begun a pediatric clinical trial with R-albuterol, the single-isomer form of albuterol. The trial aims to show that nebulized R-albuterol is as safe and effective as racemic albuterol. This conclusion was demonstrated in Sepracor's Phase II trial with the product in adults. Use of R-albuterol was also associated with less cardiac side effects and tremor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze